Haptide-coated collagen sponge as a bioactive matrix for tissue regeneration

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 84, Issue 2, 2008, Pages 571-583

  Marx, Gerard ^a   Hotovely Salomon, Anna ^a   Levdansky, Lila ^b   Gaberman, Elena ^b   Snir, Ganit ^a   Sievner, Zaki ^c   Klauzner, Yakir ^a   Silberklang, Melvin ^d   Thomas, Dolly ^d   Hoffman, Nataly ^d   Luke, Sunny ^d   Lesnoy, Daniel ^d   Gorodetsky, Raphael ^a,b  

^a HAPTO Biotech Ltd   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d Ortec International Inc   (United States)

Author keywords

Collagen; Fibrinogen; Haptide; Tissue augmentation; Wound healing

Indexed keywords

ADVERSE REACTIONS; FIBRINOGEN; HAPTIDE; TISSUE AUGMENTATION; WOUND HEALING;

BIOMATERIALS; CELL ADHESION; CROSSLINKING; FIBROBLASTS; HISTOLOGY; SKIN; TISSUE;

COLLAGEN;

BIOMATERIAL; COLLAGEN SPONGE; COLLAGEN TYPE 1; CYANAMIDE; FIBRINOGEN; HAPTIDE; PEPTIDE DERIVATIVE; REAGENT; SODIUM HYDROXIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL ADHESION; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; COW; CROSS LINKING; DEGRADATION; ENDOTHELIUM CELL; HALF LIFE TIME; HUMAN; HUMAN CELL; INFLAMMATION; NONHUMAN; SKIN FIBROBLAST; TISSUE REGENERATION; WOUND HEALING;

ANIMALS; CATTLE; CELL ADHESION MOLECULES; CELLS, CULTURED; COATED MATERIALS, BIOCOMPATIBLE; COLLAGEN; GUIDED TISSUE REGENERATION; HUMANS; PEPTIDES; RATS; SKIN, ARTIFICIAL; TISSUE SCAFFOLDS; WOUND HEALING;

EID: 38349187954     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.30905     Document Type: Article

References (50)

1. Martin P. Wound healing - Aiming for perfect skin regeneration. Science 1997;276:75-81.
2. Eisenbud D, Huang, N, Luke, S, Silberklang, M. Skin substitutes and wound healing: Current status and challenges. Wounds 2004;16:2-17.
3. Bello YM, Falabella AF, Eaglstein WH. Tissue-engineered skin. Current status in wound healing. Am J Clin Dermatol 2001;2:305-313.
4. Jones I, Currie L, Martin R. A guide to biological skin substitutes. Br J Plast Surg 2002;55:185-193.
5. Machens HG, Berger AC, Mailaender P. Bioartificial skin (Review). Cells Tissues Organs 2000;167:88-94.
6. Hansen SL, Voigt DW, Wiebelhaus P, Paul CN. Using skin replacement products to treat burns and wounds. Adv Skin Wound Care 2001;14:37-44.
7. Beele H. Artificial skin: past, present and future. Int J Artif Organs 2002;25:163-173.
8. Omar AA, Mavor AI, Jones AM, Homer-Vanniasinkam S. Treatment of venous leg ulcers with Dermagraft. Eur J Vasc Endovasc Surg 2004;27:666-672.
9. Eisenberg M, Llewelyn D. Surgical management of hands in children with recessive dystrophic epidermolysis bullosa: Use of allogeneic composite cultured skin grafts. Br J Plast Surg 1998;51:608-613.
10. Still J, Glat P, Silverstein P, Griswold J, Mozingo D. The use of a collagen sponge/living cell composite material to treat donor sites in burn patients. Burns 2003;29:837-841.
11. Martin LK, Kirsner RS. Use of a meshed bilayered cellular matrix to treat a venous ulcer. Adv Skin Wound Care 2002;15:260, 262, 264.
12. Lipkin SCE, Isseroff Z, Silverstein P. Effectiveness of bilayered cellular matrix in healing of neuropathic diabetic foot ulcers: Results of a multicenter pilot trial. Wounds 2003;15:230-236.
13. Griffiths M, Ojeh N, Livingstone R, Price R, Navsaria H. Survival of Apligraf in acute human wounds. Tissue Eng 2004;10:1180-1195.
14. Phillips TJ, Manzoor J, Rojas A, Isaacs C, Carson P, Sabolinski M, Young J, Falanga V. The longevity of a bilayered skin substitute after application to venous ulcers. Arch Dermatol 2002;138:1079-1081.
15. King WW, Lam PK, Liew CT, Ho WS, Li AK. Evaluation of artificial skin (Integra) in a rodent model. Burns 1997;23(Suppl 1):S30-S32.
16. Chu CS, McManus AT, Matylevich NP, Goodwin CW, Pruitt BA Jr. Integra as a dermal replacement in a meshed composite skin graft in a rat model: A one-step operative procedure. J Trauma 2002;52:122-129.
17. Soiderer EE, Lantz GC, Kazacos EA, Hodde JP, Wiegand RE. Morphologic study of three collagen materials for body wall repair. J Surg Res 2004;118:161-175.
18. Hodde J. Naturally occurring scaffolds for soft tissue repair and regeneration. Tissue Eng 2002;8:295-308.
19. Poulose BK, Scholz S, Moore DE, Schmidt CR, Grogan EL, Lao OB, Nanney L, Davidson J, Holzman MD. Physiologic properties of small intestine submucosa. J Surg Res 2005;123:262-267.
20. Mostow EN, Haraway GD, Dalsing M, Hodde JP, King D. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: A randomized clinical trial. J Vasc Surg 2005;41:837-843.
21. Brown-Etris M, Cutshall WD, Hiles MC. A new biomaterial derived from small intestine submucosa and developed into a wound matrix device. Wounds 2002;143:150-166.
22. Wainwright D, Madden M, Luterman A, Hunt J, Monafo W, Heimbach D, Kagan R, Sittig K, Dimick A, Herndon D. Clinical evaluation of an acellular allograft dermal matrix in full-thickness burns. J Burn Care Rehabil 1996;17:124-136.
23. Wang XH, Li DP, Wang WJ, Feng QL, Cui FZ, Xu YX, Song XH, van der Werf M. Crosslinked collagen/chitosan matrix for artificial livers. Biomaterials 2003;24:3213-3220.
24. Wissink MJ, Beernink R, Poot AA, Engbers GH, Beugeling T, van Aken WG, Feijen J. Improved endothelialization of vascular grafts by local release of growth factor from heparinized collagen matrices. J Control Release 2000;64:103-114.
25. Steffens GC, Yao C, Prevel P, Markowicz M, Schenck P, Noah EM, Pallua N. Modulation of angiogenic potential of collagen matrices by covalent incorporation of heparin and loading with vascular endothelial growth factor. Tissue Eng 2004;10:1502-1509.
26. Park SN, Lee HJ, Lee KH, Suh H. Biological characterization of EDC-crosslinked collagen-hyaluronic acid matrix in dermal tissue restoration. Biomaterials 2003;24:1631-1641.
27. Shin H, Jo S, Mikos AG. Biomimetic materials for tissue engineering. Biomaterials 2003;24:4353-4364.
28. Grzesiak JJ, Pierschbacher MD, Amodeo MF, Malaney TI, Glass JR. Enhancement of cell interactions with collagen/glycosaminoglycan matrices by RGD derivatization. Biomaterials 1997;18:1625-1632.
29. Chen J, Altman GH, Karageorgiou V, Horan R, Collette A, Volloch V, Colabro T, Kaplan DL. Human bone marrow stromal cell and ligament fibroblast responses on RGD-modified silk fibers. J Biomed Mater Res A 2003;67:559-570.
30. Hanks T, Atkinson BL. Comparison of cell viability on anorganic bone matrix with or without P-15 cell binding peptide. Biomaterials 2004;25:4831-4836.
31. Healy KE, Rezania A, Stile RA. Designing biomaterials to direct biological responses. Ann NY Acad Sci 1999;875:24-35.
32. Hsu SH, Chang SH, Yen HJ, Whu SW, Tsai CL, Chen DC. Evaluation of biodegradable polyesters modified by type II collagen and Arg-Gly-Asp as tissue engineering scaffolding materials for cartilage regeneration. Artif Organs 2006;30:42-55.
33. Zhang L, Hum M, Wang M, Li Y, Chen H, Chu C, Jiang H. Evaluation of modifying collagen matrix with RGD peptide through periodate oxidation. J Biomed Mater Res A 2005;73:468-475.
34. Kim JE, Kim SJ, Jeong HW, Lee BH, Choi JY, Park RW, Park JY, Kim IS. RGD peptides released from beta ig-h3, a TGF-beta-induced cell-adhesive molecule, mediate apoptosis. Oncogene 2003;22:2045-2053.
35. Nishizawa Y, Fukai F, Natori Y, Kato R, Tanuma S, Katayama T. Mesangial cell apoptosis induced by a fibronectin fragment. Apoptosis 1998;3:407-412.
36. Hadden HL, Henke CA. Induction of lung fibroblast apoptosis by soluble fibronectin peptides. Am J Respir Crit Care Med 2000;162:1553-1560.
37. Zanin-Zhorov A, Hershkoviz R, Hecht I, Cahalon L, Lider O. Fibronectin-associated Fas ligand rapidly induces opposing and time-dependent effects on the activation and apoptosis of T cells. J Immunol 2003;171:5882-5889.
38. Mitra A, Mulholland J, Nan A, McNeill E, Ghandehari H, Line BR. Targeting tumor angiogenic vasculature using polymer-RGD conjugates. J Control Release 2005;102:191-201.
39. Gorodetsky R, Vexler A, Shamir M, An J, Levdansky L, Shimeliovich I, Marx G. New cell attachment peptide sequences from conserved epitopes in the carboxy termini of fibrinogen. Exp Cell Res 2003;287:116-129.
40. Marx G, Ben-Moshe M, Magdassi S, Gorodetsky R. Fibrinogen C-terminal peptidic sequences (Haptides) modulate fibrin polymerization. Thromb Haemost 2004;91:43-51.
41. Gorodetsky R, Levdansky L, Vexler A, Shimeliovich I, Kassis I, Ben-Moshe M, Magdassi S, Marx G. Liposome transduction into cells enhanced by haptotactic peptides (Haptides) homologous to fibrinogen C-termini. J Control Release 2004;95:477-488.
42. Doillon CJ, Whyne CF, Brandwein S, Silver FH. Collagen-based wound dressings: Control of the pore structure and morphology. J Biomed Mater Res 1986;20:1219-1228.
43. Law JK, Parsons JR, Silver FH, Weiss AB. An evaluation of purified reconstituted type 1 collagen fibers. J Biomed Mater Res 1989;23:961-977.
44. Fields R. The measurement of amino groups in proteins and peptides. Biochem J 1971;124:581-590.
45. Puleo DA. Activity of enzyme immobilized on silanized CoCr-Mo. J Biomed Mater Res 1995;29:951-957.
46. Young JJ, Cheng KM, Tsou TL, Liu HW, Wang HJ. Preparation of cross-linked hyaluronic acid film using 2-chloro-1-methylpyridinium iodide or water-soluble 1-ethyl-(3,3-dimethylaminopropyl)carbodiimide. J Biomater Sci Polym Ed 2004;15:767-780.
47. Diamond AM, Gorham SD, Etherington DJ, Robertson JG, Light ND. The effect of modification on the susceptibility of collagen to proteolysis. I. Chemical modification of amino acid side chains. Matrix 1991;11:321-329.
48. Tiller JC, Bonner G, Pan LC, Klibanov AM. Improving biomaterial properties of collagen films by chemical modification. Biotechnol Bioeng 2001;73:246-252.
49. Zangi L, Rivkin R, Kassis I, Levdansky L, Marx G, Gorodetsky R. High-yield isolation, expansion, and differentiation of rat bone marrow-derived mesenchymal stem cells with fibrin microbeads. Tissue Eng 2006;12:2343-2354.
50. Klein AW. Skin filling. Collagen and other injectables of the skin. Dermatol Clin 2001;19:491-508.